½ÃÀ庸°í¼­
»óǰÄÚµå
1567779

ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ª ºÐ¼® - À¯Çüº°, Áø´Üº°, Ä¡·áº°, Á¾º°, Áúȯ¿øº°, Åõ¿© °æ·Îº°

North America Aquatic Veterinary Market Forecast to 2030 - Regional Analysis - by Type, Diagnostic, Treatment, Species, Diseases Source, and Route of Administration

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 109 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀåÀº 2022³â 5¾ï 5,703¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2030³â¿¡´Â 7¾ï 5,198¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 3.8%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¾ç½Ä »ê¾÷ ¹ßÀüÀ» À§ÇÑ Á¤ºÎÀÇ ³ë·ÂÀ¸·Î ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå Ȱ¼ºÈ­

¼ö»ê¹°¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä¿Í ÀÚ¿¬»ê ¾î·ùÀÇ ¿¬°£ ¾îȹ·® °¨¼Ò´Â ¾ç½Ä¾÷ÀÇ ¼ºÀåÀ» Å©°Ô ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. µû¶ó¼­ °¢±¹ Á¤ºÎ´Â ¾ç½Ä¾÷ÀÇ ¼ºÀåÀ» °³¼±Çϰí Áö¿øÇϱâ À§ÇÑ ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÃëÇϰí ÀÖ½À´Ï´Ù. ¾Æ·¡´Â ÃÖ±Ù ÃßÁø ÁßÀÎ Á¶Ä¡µéÀÔ´Ï´Ù.

2021³â 2¿ù, ¹Ì±¹ ½Äǰ³ó¾÷¿¬±¸Àç´Ü(FFAR)Àº Æ¿¶óÇÇ¾Æ È£¼ö ¹ÙÀÌ·¯½º °¨¿° ¹× ±âŸ Áúº´ÀÇ ¾ç½Ä ºÐ¾ß È®»êÀ» ¹æÁöÇÏ´Â ¹é½Å °ø±Þ ½Ã½ºÅÛÀ» ±¸ÃàÇϱâ À§ÇØ 79¸¸326´Þ·¯ÀÇ ÀÚ±ÝÀ» Á¶´ÞÇß½À´Ï´Ù.

¾¾±×·£Æ® ÇØ¾ç ¾ç½Ä º¸Á¶±Ý ÇÁ·Î±×·¥: ÀÌ Àü±¹ ±Ô¸ðÀÇ °æÀï º¸Á¶±Ý ÇÁ·Î±×·¥Àº Á¤½Ä ¸íĪÀº 'Àü±¹ ÇØ¾ç ¾ç½Ä ÀÌ´Ï¼ÅÆ¼ºê(NMAI)'·Î, ¹Ì±¹¿¡¼­ Áö¼Ó°¡´ÉÇÑ ÇØ¾ç ¾ç½ÄÀ» ÃËÁøÇϱâ À§ÇÑ ¿¬±¸ ¹× ½ÇÁõ ³ë·ÂÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù.

2022³â, ¹Ì ³ó¹«ºÎ »êÇÏ ±¹¸³½Ä·®³ó¾÷¿¬±¸¼Ò(NIFA)´Â Àü ¼¼°è ³ó¾÷ ºÎ¹®¿¡ ¼ö½Ê¾ï ´Þ·¯ÀÇ ÇÇÇØ¸¦ ÀÔÈ÷´Â °¡Ãà Áúº´¿¡ ´ëÇÑ »õ·Î¿î Ä¡·á¹ý°ú ¿¹¹æ¹ýÀ» ¿¬±¸Çϱâ À§ÇØ 1,300¸¸ ´Þ·¯ ÀÌ»óÀÇ ¿¬±¸ ÅõÀÚ¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ¿©±â¿¡´Â ¸Þ±âÀÇ Àå³» ÆÐÇ÷ÁõÀ» ¾ÈÀüÇϰí À¯¿ëÇÏ°Ô ¿¹¹æÇÏ´Â µ¥ »ç¿ëÇÒ ¼ö ÀÖ´Â Ç×±Õ »ç·á ÷°¡Á¦¸¦ Æò°¡Çϱâ À§ÇØ ¹Ì½Ã½ÃÇÇ ÁÖ¸³´ëÇп¡ 62¸¸ 5,000´Þ·¯ÀÇ º¸Á¶±ÝÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ Á¶»ç´Â ¾ç½Ä »ý»êÀÚÀÇ Ä¡·á ¿É¼ÇÀ» °³¹ßÇÏ°í »ý»ê È¿À²¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ ±â¿©ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌó·³ ¾ç½Ä »ê¾÷ ¹ßÀüÀ» Áö¿øÇÏ´Â Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºêÀÇ Áõ°¡´Â ½ÅÈï±¹ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå °³¿ä

¹Ì±¹ ÇØ¾ç´ë±âû(NOAA)¿¡ µû¸£¸é, ¾ç½Ä¾÷Àº ¹Ì±¹¿¡¼­ ¿¬°£ ¾à 15¾ï ´Þ·¯ÀÇ ¼öÀÍÀ» âÃâÇÕ´Ï´Ù. ¼¼°èÀºÇà¿¡ µû¸£¸é ¹Ì±¹Àº ¾ç½Ä¾÷À» ÅëÇØ ¾à 44¸¸ 8,000ÅæÀÇ Á¦Ç°À» »ý»êÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¼Ò½ÄÅë¿¡ µû¸£¸é 2021³â ºÏ¹Ì ¾ç½Ä¾÷ÀÌ »ý»êÇÑ ¾î·ù´Â 560¸¸ ¸¶¸®·Î ÀÌ Áß ¹Ì±¹ÀÌ »ý»êÇÑ ¾î·ù´Â 470¸¸ ¸¶¸®·Î ÀÌ Áö¿ª Àüü ¾î·ù »ý»ê·®ÀÇ 83%¸¦ Â÷ÁöÇÑ´Ù°í ÇÕ´Ï´Ù. ÆÄ¿îµå(47¾ï ´Þ·¯ »ó´ç)¸¦ ¾îȹÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ ³ª¶óÀÇ ³¬½Ã²ÛµéÀº 2020³â¿¡ °ÅÀÇ 2¾ï ȸ¿¡ °¡±î¿î ·¹Å©¸®¿¡ÀÌ¼Ç ³¬½Ã¸¦ Áñ°å½À´Ï´Ù. ÀÌ ·¹Å©¸®¿¡ÀÌ¼Ç ³¬½Ã²ÛµéÀº ¾à 10¾ï ¸¶¸®ÀÇ ¹°°í±â¸¦ Àâ¾Ò°í, ÀâÀº ¹°°í±âÀÇ 65%¸¦ ¹æ·ùÇß½À´Ï´Ù. Àüü ·¹Å©¸®¿¡ÀÌ¼Ç ¾îȹ·®Àº 34¾ï 4,000¸¸ ¸¶¸®, ¹«°Ô´Â 35¾ï 3,300¸¸ ÆÄ¿îµå¿¡ ´ÞÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌó·³ ¾ç½Ä¾÷ÀÇ ¹ø¿µÀº ¹Ì±¹ÀÇ ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

2020³â 9¿ù, ºô¹é ±×·ìÀº R&D »ý¹°ÇÐ Àü¹® µ¿¹° À§»ý ±â¾÷ IctyogroupÀ¸·ÎºÎÅÍ ´Ù¾çÇÑ Æ¿¶óÇÇ¾Æ ¹é½ÅÀ» ÀμöÇß½À´Ï´Ù. ÀÌ ±×·ìÀº ÀÌ·¯ÇÑ µî·ÏµÈ ÀÚ°¡ ¹é½ÅÀÇ Àü ¼¼°è À¯Åë ¹× ÆÇ¸Å±ÇÀ» ȹµæÇß½À´Ï´Ù. ¾ç»ç´Â ¾ÆÄí¾Æºô¹é ºÎ¹®À» À§ÇÑ »õ·Î¿î Á¦Á¦ ¹× ¹é½Å °³¹ßÀ» À§ÇØ Çù·ÂÇϱâ·Î Çß½À´Ï´Ù. À̹ø °è¾àÀ¸·Î ±â¼ú ¸¶ÄÉÆÃ Áö¿ø ¹× R&D »ý¹°ÇÐ Àü¹® Á÷¿ø ¸î ¸íÀÌ ÀÌũƼ¿À ±×·ì¿¡¼­ ºô¹éÀ¸·Î ÀÌÁ÷Çß½À´Ï´Ù.

2020³â 7¿ù, Á¶¿¡Æ¼½º´Â º¥Ä¡¸¶Å© Ȧµù½º(Benchmark Holdings, PLC)·ÎºÎÅÍ Çǽ¬ º£Æ® ±×·ì(Fish Vet Group)À» ÀμöÇÏ¿© Á¦¾à »ç¾÷À» Àü·«ÀûÀ¸·Î °­È­Çß½À´Ï´Ù. Á¶¿¡Æ¼½ºÀÇ Á¦¾à »ç¾÷Àº ¾î·ù ¹é½ÅÀÇ »óǰȭ ¹× °³¹ß, ¾ç½Ä¿ë ¹é½Å Á¢Á¾ ¹× Áø´Ü ¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, Fish Vet GroupÀÇ Àμö´Â Á¶¿¡Æ¼½º°¡ PharmaqÀÇ ÂüÁ¶ ½ÇÇè½Ç¿¡¼­ ȯ°æ Å×½ºÆ®¸¦ Æ÷ÇÔÇÑ Áø´Ü Àü¹® Áö½Ä°ú Å×½ºÆ® ¼­ºñ½º¸¦ °­È­ÇÏ´Â µ¥ µµ¿òÀÌ µÇ¾ú½À´Ï´Ù. ÀÌó·³ ¹Ì±¹ ¾ç½Ä¾÷°èÀÇ ´Ù¾çÇÑ ½ÃÀå ±â¾÷ÀÇ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê´Â ¹Ì±¹ ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀåÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå ¼¼ºÐÈ­

ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀåÀº À¯Çü, Á¾, Áúº´ ¿øÀÎ, ±âŸ Åõ¿© °æ·Î, ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

À¯Çüº°·Î ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀåÀº Áø´Ü°ú Ä¡·á·Î ³ª´µ¸ç, 2022³â¿¡´Â Ä¡·á ºÎ¹®ÀÌ ´õ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Áø´Ü ºÎ¹®Àº Ç÷ûÇÐ, ºÐÀÚÇÐ, DNA ½ÃÄö½Ì ¹× ±âŸ Áø´ÜÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù. Ä¡·á ºÐ¾ß´Â ¹é½Å, ÀǾàǰ ¹× º¸ÃæÁ¦·Î ¼¼ºÐÈ­µË´Ï´Ù.

À¯Çüº°·Î ºÏ¹Ì ¼ö»ýµ¿¹° ½ÃÀåÀº ¾î·ù, °©°¢·ù, ¿¬Ã¼µ¿¹°, ±âŸ·Î ±¸ºÐµÇ¸ç, 2022³â¿¡´Â ¾î·ù ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Áúº´ÀÇ ¿øÀο¡ µû¶ó ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀåÀº ¼¼±Õ, ¹ÙÀÌ·¯½º, ±â»ýÃæ, ±âŸ·Î ±¸ºÐµË´Ï´Ù. ¹ÚÅ׸®¾Æ ºÎ¹®ÀÌ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Åõ¾à °æ·Î¿¡ µû¶ó ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀåÀº ¼ö¾×Á¦, ¾à¿ë »ç·á ¹× ±âŸ Åõ¾à °æ·Î·Î ±¸ºÐµÇ¸ç, 2022³â¿¡´Â ¼ö¾×Á¦ Åõ¾à ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ³ª´µ¸ç, 2022³â ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå Á¡À¯À²Àº ¹Ì±¹ÀÌ µ¶Â÷ÁöÇß½À´Ï´Ù.

Aquatic Diagnostics Ltd, Ceva Polchem Pvt Ltd, Elanco Animal Health Inc, HIPRA SA, Merck KGaA, Phibro Animal Health Corp, Thermo Fisher Scientific Inc, Virbac SA, Zoetis Inc µîÀÌ ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå »óȲ

  • ºÏ¹ÌÀÇ PEST ºÐ¼®

Á¦5Àå ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ö»ê¾ç½Ä »ê¾÷ ¹ßÀü¿¡ ´ëÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê
    • ¼ö»ýµ¿¹°Á¾ ¼Òºñ ¼ö¿ä ±ÞÁõ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¹é½Å ½ÂÀο¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
  • ½ÃÀå ±âȸ
    • ½Å±Ô ¾î·ù ¹é½Å °³¹ß
  • ÇâÈÄ µ¿Çâ
    • ¾î·ù ¹é½ÅÀÇ ±â¼úÀû Áøº¸
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦6Àå ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå : ºÏ¹Ì ½ÃÀå ºÐ¼®

  • ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå ¸ÅÃâ, 2020-2030³â

Á¦7Àå ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå ºÐ¼® : À¯Çüº°

  • Áø´Ü
  • Ä¡·á

Á¦8Àå ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå ºÐ¼® : Á¾º°

  • ¾î·ù
  • °©°¢·ù
  • ¿¬Ã¼µ¿¹°
  • ±âŸ

Á¦9Àå ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå ºÐ¼® : Áúȯ¿øº°

  • ¼¼±Õ¼º
  • ¹ÙÀÌ·¯½º
  • ±â»ýÃæ
  • ±âŸ

Á¦10Àå ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå ºÐ¼® : Åõ¿© °æ·Îº°

  • ¹°¾à
  • ¾à¿ë »ç·á
  • ±âŸ Åõ¿© °æ·Î

Á¦11Àå ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå : ±¹°¡º°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ

Á¦12Àå ¾÷°è »óȲ

  • ºÏ¹ÌÀÇ ¼ö»ê¿ë ¼öÀÇÇÐ ½ÃÀå ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«

Á¦13Àå ±â¾÷ °³¿ä

  • Zoetis Inc
  • Merck KGaA
  • HIPRA SA
  • Ceva Polchem Pvt Ltd
  • Virbac SA
  • Elanco Animal Health Inc
  • Phibro Animal Health Corp
  • Aquatic Diagnostics Ltd
  • Thermo Fisher Scientific Inc

Á¦14Àå ºÎ·Ï

ksm 24.10.24

The North America aquatic veterinary market was valued at US$ 557.03 million in 2022 and is expected to reach US$ 751.98 million by 2030; it is estimated to register a CAGR of 3.8% from 2022 to 2030.

Government Initiatives to Develop Aquaculture Industry Fuel North America Aquatic Veterinary Market

The high demand for seafood and the decreasing annual catch of wild fish are crucial factors that can drive the growth of the aquaculture industry at an exponential rate. Thus, governments are taking initiatives to improve and support the growth of the aquacultural industry. Following are a few recent initiatives:

In February 2021, the Foundation for Food & Agriculture Research (FFAR) raised funds of US$ 790,326 to create a vaccine delivery system to prevent the spread of tilapia lake virus infections and other diseases in the aquaculture sector.

Sea Grant Marine Aquaculture Grant Program: This nationwide competitive grant program, officially known as the "National Marine Aquaculture Initiative (NMAI)," promotes research and demonstration initiatives to advance sustainable marine aquaculture in the US.

In 2022, the USDA National Institute of Food and Agriculture (NIFA) announced a research investment of more than US$ 13 million to investigate new treatments and preventative measures for animal illnesses that cost the global agriculture sector billions of dollars. This included a US$ 625,000 grant to Mississippi State University to assess an antibacterial feed additive that can be used to prevent enteric septicemia in catfish in a secure and useful manner. This study will contribute to developing aquaculture producers' treatment alternatives, improving production efficiency. Thus, an increase in government initiatives to support developments in the aquaculture industry drives the aquatic veterinary market growth.

North America Aquatic Veterinary Market Overview

According to the National Oceanic and Atmospheric Administration, aquaculture generates ~US$ 1.5 billion annually in the US. The World Bank states that the US produced ~448 thousand metric ton of products out of aquaculture. As per the same source, ~5.6 million fishes were produced by the North American aquaculture industry in 2021, of which the US accounted for the production of ~4.7 million, i.e., ~83% of the total regional fish production. According to the Fisheries of the US 2020 report, commercial fishermen in the US landed 8.4 billion pounds valued at US$ 4.7 billion in 2020. Anglers in the country took nearly 200 million trips for recreational fisheries in 2020. These recreational anglers caught approximately 1 billion fish and released 65% of those caught. The overall recreational harvest was estimated at 344 million fish weighing 353 million pounds. Thus, the flourishing aquaculture industry fuels the growth of the North America aquatic veterinary market in the US.

In September 2020, the Virbac Group acquired various tilapia vaccines from Ictyogroup, an animal health company specializing in R&D biology. The group received rights for the distribution and marketing of these registered, autogenous vaccines worldwide. The two companies had a partnership for the development of new formulations and new vaccines for the Aqua Virbac division. The agreement also allowed the transfer of several employees specialized in technical marketing support and R&D biology from Ictyogroup to Virbac.

In July 2020, Zoetis acquired Fish Vet Group from Benchmark Holdings, PLC to make a strategic addition to its pharma business. The pharmaceutical business of Zoetis commercializes and develops fish vaccines and offers vaccination and diagnostic services for aquaculture. The acquisition of Fish Vet Group helped Zoetis enhance its diagnostics expertise and testing services, including environmental testing, that Pharmaq's reference lab. Thus, strategic initiatives by various market players in the US aquaculture industry bolster the North America aquatic veterinary market in the US.

North America Aquatic Veterinary Market Revenue and Forecast to 2030 (US$ Million)

North America Aquatic Veterinary Market Segmentation

The North America aquatic veterinary market is categorized into type, species, diseases source, other route of administration, and country.

Based on type, the North America aquatic veterinary market is bifurcated diagnostic and treatment. The treatment segment held a larger market share in 2022. The diagnostic segment is further sub segmented into serological, molecular, DNA sequencing, and other diagnostics. The treatment segment is further sub segmented into vaccines, medications, and supplements.

By species, the North America aquatic veterinary market is segmented into fish, crustaceans, mollusca, and others. The fish segment held the largest market share in 2022.

Based on diseases source, the North America aquatic veterinary market is segmented into bacterial, viral, parasites, and others. The bacterial segment held the largest market share in 2022.

In terms of route of administration, the North America aquatic veterinary market is segmented into water medication, medicated feed, and other route of administrations. The water medication segment held the largest market share in 2022.

By country, the North America aquatic veterinary market is segmented into the US, Canada, and Mexico. The US dominated the North America aquatic veterinary market share in 2022.

Aquatic Diagnostics Ltd, Ceva Polchem Pvt Ltd, Elanco Animal Health Inc, HIPRA SA, Merck KGaA, Phibro Animal Health Corp, Thermo Fisher Scientific Inc, Virbac SA, and Zoetis Inc are some of the leading companies operating in the North America aquatic veterinary market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Aquatic Veterinary Market Landscape

  • 4.1 North America PEST Analysis

5. North America Aquatic Veterinary Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Government Initiatives to Develop Aquaculture Industry
    • 5.1.2 Surging Demand for Aquatic Animal Species for Consumption
  • 5.2 Market Restraints
    • 5.2.1 Stringent Regulations for Vaccine Approvals
  • 5.3 Market Opportunities
    • 5.3.1 Development of Novel Fish Vaccines
  • 5.4 Future Trends
    • 5.4.1 Technological Advancements in Fish Vaccines
  • 5.5 Impact of Drivers and Restraints:

6. Aquatic Veterinary Market - North America Market Analysis

  • 6.1 North America Aquatic Veterinary Market Revenue (US$ Million), 2020-2030

7. North America Aquatic Veterinary Market Analysis - by Type

  • 7.1 Diagnostic
    • 7.1.1 Overview
    • 7.1.2 Diagnostic: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Treatment
    • 7.2.1 Overview
    • 7.2.2 Treatment: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Aquatic Veterinary Market Analysis - by Species

  • 8.1 Fish
    • 8.1.1 Overview
    • 8.1.2 Fish: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Crustaceans
    • 8.2.1 Overview
    • 8.2.2 Crustaceans: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Mollusca
    • 8.3.1 Overview
    • 8.3.2 Mollusca: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Aquatic Veterinary Market Analysis - by Diseases Source

  • 9.1 Bacterial
    • 9.1.1 Overview
    • 9.1.2 Bacterial: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.2 Viral
    • 9.2.1 Overview
    • 9.2.2 Viral: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Parasites
    • 9.3.1 Overview
    • 9.3.2 Parasites: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Aquatic Veterinary Market Analysis - by Route of Administration

  • 10.1 Water Medication
    • 10.1.1 Overview
    • 10.1.2 Water Medication: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.2 Medicated Feed
    • 10.2.1 Overview
    • 10.2.2 Medicated Feed: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Other Route of Administrations
    • 10.3.1 Overview
    • 10.3.2 Other Route of Administrations: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Aquatic Veterinary Market - Country Analysis

  • 11.1 North America
    • 11.1.1 North America Aquatic Veterinary Market - Revenue and Forecast Analysis - by Country
      • 11.1.1.1 North America Aquatic Veterinary Market - Revenue and Forecast Analysis - by Country
      • 11.1.1.1 US
      • 11.1.1.2 US: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.2.1 US: North America Aquatic Veterinary Market Breakdown, by Type
        • 11.1.1.2.1.1 US: North America Aquatic Veterinary Market Breakdown, by Diagnostic
        • 11.1.1.2.1.2 US: North America Aquatic Veterinary Market Breakdown, by Treatment
        • 11.1.1.2.2 US: North America Aquatic Veterinary Market Breakdown, by Species
        • 11.1.1.2.3 US: North America Aquatic Veterinary Market Breakdown, by Diseases Source
        • 11.1.1.2.4 US: North America Aquatic Veterinary Market Breakdown, by Route Of Administration
      • 11.1.1.3 Canada
      • 11.1.1.4 Canada: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.4.1 Canada: North America Aquatic Veterinary Market Breakdown, by Type
        • 11.1.1.4.1.1 Canada: North America Aquatic Veterinary Market Breakdown, by Diagnostic
        • 11.1.1.4.1.2 Canada: North America Aquatic Veterinary Market Breakdown, by Treatment
        • 11.1.1.4.2 Canada: North America Aquatic Veterinary Market Breakdown, by Species
        • 11.1.1.4.3 Canada: North America Aquatic Veterinary Market Breakdown, by Diseases Source
        • 11.1.1.4.4 Canada: North America Aquatic Veterinary Market Breakdown, by Route Of Administration
      • 11.1.1.5 Mexico
      • 11.1.1.6 Mexico: North America Aquatic Veterinary Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.6.1 Mexico: North America Aquatic Veterinary Market Breakdown, by Type
        • 11.1.1.6.1.1 Mexico: North America Aquatic Veterinary Market Breakdown, by Diagnostic
        • 11.1.1.6.1.2 Mexico: North America Aquatic Veterinary Market Breakdown, by Treatment
        • 11.1.1.6.2 Mexico: North America Aquatic Veterinary Market Breakdown, by Species
        • 11.1.1.6.3 Mexico: North America Aquatic Veterinary Market Breakdown, by Diseases Source
        • 11.1.1.6.4 Mexico: North America Aquatic Veterinary Market Breakdown, by Route Of Administration

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in North America Aquatic Veterinary Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Zoetis Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Merck KGaA
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 HIPRA SA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Ceva Polchem Pvt Ltd
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Virbac SA
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Elanco Animal Health Inc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Phibro Animal Health Corp
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Aquatic Diagnostics Ltd
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Thermo Fisher Scientific Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦